Tesamorelin Peptide: What the Clinical Trials Show

The short version

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone, GHRH(1-44), approved by the FDA in November 2010 under BLA 022505 for one narrow use: reducing excess abdominal fat in adults with HIV who have lipodystrophy.^[3] It is one of the very few peptides discussed in the research-peptide market that carries a real phase 3 evidence base — two adequately powered randomized trials totaling 806 patients, and a label with hard numbers in it.^[5] It is also one of the few whose label explicitly says it is not a weight-loss drug.^[1]

That combination is what makes the tesamorelin record worth reading carefully. The trials are good. The question people usually bring to them is a question the trials never asked.

What tesamorelin is, structurally and mechanistically

Tesamorelin is GHRH(1-44) with a trans-3-hexenoyl group attached to the N-terminus. That modification is what makes it a drug rather than a laboratory curiosity: unmodified GHRH is degraded almost instantly by dipeptidyl peptidase-4, and the acylation slows that enough for a subcutaneous dose to reach the pituitary.

Per the FDA label, tesamorelin binds and stimulates human GRF receptors, which stimulates the synthesis and pulsatile release of endogenous growth hormone.^[1] The word pulsatileis doing real work there. Tesamorelin is not growth hormone. It acts one step upstream, leaving the pituitary’s own feedback loops in place, which is the mechanistic argument for why it produced fewer glucose problems than exogenous GH did in earlier HIV lipodystrophy studies. The same class logic underlies the CJC-1295 and ipamorelin record, where the trial evidence is far thinner.

What it is approved for, and what the label rules out

The indication on the current EGRIFTA WR label reads: indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.^[1]

The Limitations of Use section is unusually blunt. It states that long-term cardiovascular safety has not been established, that the drug is not indicated for weight loss management, and that there are no data supporting improved compliance with antiretroviral therapy.

Three formulations have been approved under the same BLA, all injected subcutaneously into the abdomen with site rotation. The original EGRIFTA (November 10, 2010) was 2 mg once daily. EGRIFTA SV (July 5, 2019) is 1.4 mg once daily.^[2]EGRIFTA WR, the concentrated F8 formulation approved March 25, 2025, is 1.28 mg once daily and is reconstituted weekly rather than daily. Which formulation and dose apply to any individual is a prescriber’s decision, not something to infer from a trial protocol.

What the pivotal phase 3 trials actually found

The registration trial, published by Falutz and colleagues in the New England Journal of Medicine in 2007, randomized 412 patients with HIV and abdominal fat accumulation (86% men) to 2 mg tesamorelin or placebo daily for 26 weeks. The primary endpoint was percent change in visceral adipose tissue by CT.^[4]

• VAT:decreased 15.2% on tesamorelin, increased 5.0% on placebo (P<0.001)
• Triglycerides:decreased 50 mg/dL versus an increase of 9 mg/dL (P<0.001)
• Total cholesterol to HDL ratio:decreased 0.31 versus an increase of 0.21 (P<0.001)
• IGF-I:increased 81.0% versus a 5.0% decrease (P<0.001)
• Glycemic measures: no significant differences between groups

The 2010 pooled analysis of both phase 3 trials covered 806 patients randomized 2:1 (543 tesamorelin, 263 placebo).^[5] At week 26, VAT changed by −24 ± 41 cm² versus +2 ± 35 cm² for placebo, a treatment effect of −15.4%. Subcutaneous abdominal fat did not change significantly (treatment effect −0.6%, P=0.08), which is the source of the claim that tesamorelin acts selectively on visceral fat. Mean IGF-I rose 108 ± 112 ng/mL versus −7 ± 64. In patients who stayed on drug through week 52, VAT reduction reached −35 ± 50 cm², or −17.5 ± 23.3%, with waist circumference down 3.4 ± 6.0 cm.

The FDA label reports the two trials separately: −18% VAT with tesamorelin (n=273) versus 2% with placebo (n=137) in Study 1, and −14% (n=270) versus −2% (n=126) in Study 2 at 26 weeks.^[1]

One methodological point matters for how you read all of this. VAT measured by CT is a surrogate endpoint, not a clinical one. The trials show fat compartments moving and lipids improving. They do not show fewer heart attacks, and the label says as much.

Response was not uniform, and stopping reverses it

A prespecified responder analysis defined responders as patients with at least an 8% VAT reduction.^[6] Among 402 patients initially randomized to tesamorelin, responders showed significantly greater triglyceride reductions and better preservation of fasting glucose and HbA1c than non-responders over 52 weeks. Non-responders drifted the wrong way on glucose: +5 mg/dL at 26 weeks versus +1 mg/dL in responders, and +8 versus −1 at 52 weeks.

A subset of patients gets the metabolic benefit and a subset does not, and the ones who do not may still carry the glucose risk.

The effect also depends on continued treatment. The phase 3 program re-randomized patients at week 26, and those switched from tesamorelin to placebo lost the benefit. A 2011 review puts it directly: cessation of either growth hormone or tesamorelin results in a prompt return of truncal obesity, and long-term maintenance strategies have not been clarified.^[9]

Liver fat and cognition: two real trials, both small

Two investigator-initiated trials extended tesamorelin beyond the lipodystrophy indication. Neither changed the label.

NAFLD in HIV. Stanley and colleagues randomized 61 people with HIV and a hepatic fat fraction of 5% or more to tesamorelin 2 mg daily or placebo for 12 months.^[7]Tesamorelin produced an absolute reduction in hepatic fat fraction of −4.1% (95% CI −7.6 to −0.7, P=0.018), a −37% relative reduction (95% CI −67 to −7, P=0.016). After 12 months, 35% of the tesamorelin group versus 4% of placebo had a hepatic fat fraction below 5% (P=0.0069). Fasting glucose and HbA1c did not differ between groups. The authors’ own conclusion was appropriately hedged: tesamorelin might be beneficial, and further study of long-term liver histology is needed.

Cognition in older adults. Baker and colleagues gave 152 adults aged 55 to 87, of whom 66 had mild cognitive impairment, 1 mg of tesamorelin or placebo subcutaneously each night for 20 weeks.^[8] The intent-to-treat analysis showed a favorable effect on a composite cognitive outcome (P=.03), driven mainly by executive function (P=.005), with verbal memory showing a non-significant trend (P=.08). IGF-1 rose 117% and body fat percentage fell 7.4%. Mild adverse events were reported by 68% of treated participants versus 36% on placebo.

This is a single 20-week trial with a composite endpoint. It has not been replicated in a phase 3 program, and it is frequently cited online as though it established a nootropic indication. It did not.

Safety signals on the label

From the 26-week controlled phase, adverse reactions reported more often on tesamorelin than placebo included injection site reactions (17% versus 6%), myalgia (6% versus 2%), peripheral edema (6% versus 2%), and arthralgia (13% versus 11%). Progression to an HbA1c of 6.5% or higher occurred in 5% versus 1%.^[1]

Contraindications are: disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy. Labeled warnings cover increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance and diabetes, hypersensitivity reactions, injection site reactions, and increased mortality in patients with acute critical illness.

The neoplasm and IGF-1 warnings are the mechanistic core of the risk profile. A drug whose entire effect runs through raising growth hormone and IGF-1 inherits the concerns that come with that axis.

Pharmacokinetics: absorption is the constraint

The EGRIFTA SV label reports absolute bioavailability of less than 4% after a subcutaneous 2 mg dose of the 1 mg/vial formulation, a median Tmax of 0.15 hours, and a mean elimination half-life of 8 minutes.^[2]

Eight minutes is extremely short, and it illustrates why a peptide’s half-life tells you little about its duration of effect. Tesamorelin is cleared before the pituitary has finished responding; the pharmacodynamic signal, a GH pulse followed by a sustained IGF-1 rise, outlasts the molecule by orders of magnitude. Reading these numbers correctly means separating exposure from effect, covered in the PK parameters guide. The low bioavailability and rapid clearance also explain why every studied protocol is subcutaneous and daily.

What the research record does not show

Naming the gaps honestly is more useful than filling them:

• No non-HIV obesity trials. Every VAT trial was conducted in people with HIV-associated lipodystrophy. Whether the same effect size appears in general obesity is untested, not disproven.
• No cardiovascular outcome data. The label states long-term cardiovascular safety has not been established. VAT reduction is a surrogate.
• No head-to-head comparisons against CJC-1295, ipamorelin, or any other GH secretagogue.
• No trials in bodybuilding, athletic performance, or anti-aging contexts at all.
• No durability data beyond 52 weeks of controlled treatment, and clear evidence that stopping reverses the effect.

Tesamorelin sold as a “research peptide” is also not the same product as the approved one. The approved formulations are lyophilized kits with defined excipients and batch release testing. Vials sold under research-use-only labeling carry no such guarantees of identity or purity, and no published data links any of them to the trial results above.